Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Texas
-
Carrollton, Texas, United States, 75006
- Stephens & Associates Dallas Research Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women
- 25-70 years
- Diagnosis of papulopustular rosacea
- Eligible for Oracea treatment
Exclusion Criteria:
- Allergies to components of investigational product and/or hypersensitivity to tetracyclines
- Taken systemic therapy directed at improving rosacea, including antibiotics, within 30 days prior to baseline visit
- Used topical rosacea treatment within 30 days prior to baseline visit
- Have active ocular rosacea and/or blepharitis/meibomianitis requiring systemic treatment by an opthalmologist
- Previously failed to have improvement of rosacea with appropriate use of systemic tetracycline family of antibiotics
- Exposed to intense/excessive ultraviolet (UV) radiation within one week prior to baseline and/or who forsee unprotected and intense/excessive UV exposure during the course of the study
- Have planned surgical procedures during the course of the study
- Have used tetracycline antibiotics within 30 days prior to baseline visit or during study
- At risk in terms of precautions, warnings, and contraindications
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Oracea
Oracea (doxycycline USP, 40mg[30mg immediate release/ 10mg delayed release beads] taken once daily in the morning on an empty stomach, one hour before meals or two hours after. Oral dose for 12 weeks |
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rosacea Score on the Visual Analog Scale
Time Frame: Baseline, Weeks 2, 6, and 12
|
VAS = visual analog scale, 10 cm scale in which 0 = no rosacea, 10 = worst rosacea imaginable
|
Baseline, Weeks 2, 6, and 12
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rosacea-Specific Quality of Life Index
Time Frame: Baseline, Weeks 2, 6, and 12
|
ROSACEA-SPECIFIC QUALITY OF LIFE INDEX©: average of scores to 22 questions on a 5 point scale (1 = never, 5 = all the time)
|
Baseline, Weeks 2, 6, and 12
|
|
Patient Global Assessment (PGA) of Rosacea Scores
Time Frame: Baseline, Weeks 2, 6, and 12
|
Patient Global Assessment (PGA) of Rosacea: 0 = clear, no signs or symptoms present; 1 = Near clear, 1 or 2 papules; 2 = mild, some (3 to 10) papules/pustules; 3 = moderate, moderate (11 to 19) number of papules and pustules; 4 = severe, numerous (≥ 20) papules/pustules; nodules
|
Baseline, Weeks 2, 6, and 12
|
|
Patient Satisfaction Question
Time Frame: Week 2, 6, and 12
|
The patient satisfaction question was answered by the subject at week 2, week 6, and week 12.
The subject was asked how satisfied they were with this treatment (doxycycline MR) for rosacea.
|
Week 2, 6, and 12
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- GLI.04.SPR.US10233
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.